NCT06726226 Extremely Preterm Respiratory Outcome Cohort
| NCT ID | NCT06726226 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Infant, Premature |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2030-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2022-06-01 with a primary completion date of 2030-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines the respiratory outcomes of preterm infants born at gestational ages less than 29 weeks, spanning from birth to 24 months corrected age. It delves into the intricacies of respiratory function impairment attributable to diverse factors, such as respiratory distress syndrome, bronchopulmonary dysplasia, postnatal corticosteroids, ventilatory support, as well as nutritional aspect during NICU stay. Furthermore, it scrutinizes the incidence of chronic respiratory diseases stemming from these conditions, assessing their long-term impact on respiratory prognosis post-discharge. In addition to respiratory aspects, the research extends its focus to the growth and developmental outcomes of preterm infants. By synthesizing these multifaceted elements, the study aspires to enhance current treatments and preventative measures for respiratory conditions in preterm infants.
Eligibility Criteria
Inclusion Criteria: * Infants born at gestational age less than 29 weeks with cohort consent obtained within 7 days of birth Exclusion Criteria: * death within 3 days of birth * severe structural heart defects * structural abnormalities in the upper airway, lungs, or chest * congenital anomalies that may impact cardiopulmonary function * follow-up is difficult until 24 months of age
Contact & Investigator
Seung Han Shin, MD, PhD
PRINCIPAL INVESTIGATOR
Seoul National University Children's Hospital
Frequently Asked Questions
Who can join the NCT06726226 clinical trial?
This trial is open to participants of all sexes, up to 7 Days, studying Infant, Premature. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06726226 currently recruiting?
Yes, NCT06726226 is actively recruiting participants. Contact the research team at revival421@snu.ac.kr for enrollment information.
Where is the NCT06726226 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06726226 clinical trial?
NCT06726226 is sponsored by Seoul National University Hospital. The principal investigator is Seung Han Shin, MD, PhD at Seoul National University Children's Hospital. The trial plans to enroll 600 participants.